company background image
TARO

Taro Pharmaceutical Industries NYSE:TARO Stock Report

Last Price

US$37.16

Market Cap

US$1.4b

7D

-3.4%

1Y

-49.8%

Updated

15 May, 2022

Data

Company Financials +
TARO fundamental analysis
Snowflake Score
Valuation1/6
Future Growth4/6
Past Performance1/6
Financial Health6/6
Dividends0/6

TARO Stock Overview

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally.

Taro Pharmaceutical Industries Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Taro Pharmaceutical Industries
Historical stock prices
Current Share PriceUS$37.16
52 Week HighUS$76.00
52 Week LowUS$35.80
Beta0.82
1 Month Change-7.10%
3 Month Change-18.60%
1 Year Change-49.75%
3 Year Change-63.04%
5 Year Change-67.48%
Change since IPO643.20%

Recent News & Updates

Shareholder Returns

TAROUS PharmaceuticalsUS Market
7D-3.4%0.2%-2.5%
1Y-49.8%9.9%-10.4%

Return vs Industry: TARO underperformed the US Pharmaceuticals industry which returned 9.9% over the past year.

Return vs Market: TARO underperformed the US Market which returned -10.4% over the past year.

Price Volatility

Is TARO's price volatile compared to industry and market?
TARO volatility
TARO Average Weekly Movement4.1%
Pharmaceuticals Industry Average Movement11.5%
Market Average Movement7.8%
10% most volatile stocks in US Market16.7%
10% least volatile stocks in US Market2.8%

Stable Share Price: TARO is less volatile than 75% of US stocks over the past 3 months, typically moving +/- 4% a week.

Volatility Over Time: TARO's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19501,417Uday Baldotahttps://www.taro.com

Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, develops, manufactures, and markets prescription and over-the-counter pharmaceutical products in the United States, Canada, Israel, and internationally. The company also develops and manufactures active pharmaceutical ingredients primarily for use in its finished dosage form products. It offers its products for various therapeutic categories comprises allergy, analgesic, antibacterial, antibiotic, anticonvulsant, antiemetic, antifungal, anti-inflammatory, anti-cancer, antiplatelet agent, antipyretic, cardiovascular, CNS, corticosteroid, cosmetic, cough and cold, dermatology, diuretic, endocrine, gastrointestinal, laxative, narcotics, neuropathic pain, neuropsychiatric, sedative/hypnotic, and topical anti-neoplastic.

Taro Pharmaceutical Industries Fundamentals Summary

How do Taro Pharmaceutical Industries's earnings and revenue compare to its market cap?
TARO fundamental statistics
Market CapUS$1.40b
Earnings (TTM)US$1.08m
Revenue (TTM)US$566.43m

1,298x

P/E Ratio

2.5x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
TARO income statement (TTM)
RevenueUS$566.43m
Cost of RevenueUS$273.71m
Gross ProfitUS$292.72m
Other ExpensesUS$291.65m
EarningsUS$1.08m

Last Reported Earnings

Dec 31, 2021

Next Earnings Date

n/a

Earnings per share (EPS)0.029
Gross Margin51.68%
Net Profit Margin0.19%
Debt/Equity Ratio0.0%

How did TARO perform over the long term?

See historical performance and comparison

Valuation

Is Taro Pharmaceutical Industries undervalued compared to its fair value and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • PE vs Industry

  • PE vs Market

  • PEG Ratio

  • PB vs Industry


1298.39x

Price to Earnings (PE) ratio

Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TARO's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate TARO's fair value for valuation analysis.


Price To Earnings Ratio

PE vs Industry: TARO is poor value based on its PE Ratio (1298.4x) compared to the US Pharmaceuticals industry average (20.4x).

PE vs Market: TARO is poor value based on its PE Ratio (1298.4x) compared to the US market (15.5x).


Price to Earnings Growth Ratio

PEG Ratio: TARO is poor value based on its PEG Ratio (8.2x)


Price to Book Ratio

PB vs Industry: TARO is good value based on its PB Ratio (0.8x) compared to the US Pharmaceuticals industry average (1.7x).


Future Growth

How is Taro Pharmaceutical Industries forecast to perform in the next 1 to 3 years based on estimates from 1 analyst?

Future Growth Score

4/6

Future Growth Score 4/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


158.7%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TARO's forecast earnings growth (158.7% per year) is above the savings rate (1.9%).

Earnings vs Market: TARO's earnings (158.7% per year) are forecast to grow faster than the US market (12.6% per year).

High Growth Earnings: earnings are expected to grow significantly over the next 3 years.

Revenue vs Market: TARO's revenue (10.8% per year) is forecast to grow faster than the US market (8% per year).

High Growth Revenue: TARO's revenue (10.8% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TARO's Return on Equity is forecast to be high in 3 years time


Past Performance

How has Taro Pharmaceutical Industries performed over the past 5 years?

Past Performance Score

1/6

Past Performance Score 1/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-48.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: TARO has a high level of non-cash earnings.

Growing Profit Margin: TARO became profitable in the past.


Past Earnings Growth Analysis

Earnings Trend: TARO's earnings have declined by 48.9% per year over the past 5 years.

Accelerating Growth: TARO has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: TARO has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (12.5%).


Return on Equity

High ROE: TARO's Return on Equity (0.1%) is considered low.


Financial Health

How is Taro Pharmaceutical Industries's financial position?

Financial Health Score

6/6

Financial Health Score 6/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Debt Coverage

  • Interest Coverage

Financial Position Analysis

Short Term Liabilities: TARO's short term assets ($1.2B) exceed its short term liabilities ($394.8M).

Long Term Liabilities: TARO's short term assets ($1.2B) exceed its long term liabilities ($31.7M).


Debt to Equity History and Analysis

Debt Level: TARO is debt free.

Reducing Debt: TARO had no debt 5 years ago.

Debt Coverage: TARO has no debt, therefore it does not need to be covered by operating cash flow.

Interest Coverage: TARO has no debt, therefore coverage of interest payments is not a concern.


Balance Sheet


Dividend

What is Taro Pharmaceutical Industries's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Future Dividend Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate TARO's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TARO's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TARO's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TARO's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as TARO has not reported any payouts.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

6.7yrs

Average management tenure


CEO

Uday Baldota (51 yo)

4.75yrs

Tenure

Mr. Uday V. Baldota has been Director at Association for Accessible Medicines. He has been the Chief Executive Officer of Taro Pharmaceutical Industries Ltd. since August 28, 2017 and served as its Co-Chie...


Leadership Team

Experienced Management: TARO's management team is seasoned and experienced (6.7 years average tenure).


Board Members

Experienced Board: TARO's board of directors are considered experienced (7.1 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

Taro Pharmaceutical Industries Ltd.'s employee growth, exchange listings and data sources


Key Information

  • Name: Taro Pharmaceutical Industries Ltd.
  • Ticker: TARO
  • Exchange: NYSE
  • Founded: 1950
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$1.397b
  • Shares outstanding: 37.58m
  • Website: https://www.taro.com

Number of Employees


Location

  • Taro Pharmaceutical Industries Ltd.
  • 14 Hakitor Street
  • Haifa Bay
  • Haifa
  • 2624761
  • Israel

Listings


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/05/15 00:00
End of Day Share Price2022/05/13 00:00
Earnings2021/12/31
Annual Earnings2021/03/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.